H. Robert Superko/a4m.com
Aug 11, 2025, 06:08
New Data From WHS and ASPREE: Aspirin Heart Disease Prevention Conundrum
Maxima Mendez, Cardiologist, CEO of Cli-Lipid and the Cardiovascular Lipid Club, shared a post on X:
“New data from WHS and ASPREE:
Aspirin and Lpa
•LPA+ genotype → higher CVD risk, aspirin reduced events significantly (NNT: 38–34)
•LPA– genotype → normal CVD risk, bleeding risk outweighs benefit (NNT: 833–250)”
Read the full article here.
Article: The aspirin heart disease prevention conundrum
Authors: H. Robert Superko, John Sninsky, Brenda Garrett․
Stay updated with Hemostasis Today.
-
Jan 12, 2026, 14:46A Behcet Disease with Aortic Thrombosis: Alexandru Stieber Shares A Peculiar Case
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies